"At AstraZeneca, we are using machine learning to analyse large quantities of gene expression data to stratify patients with heart failure into novel molecular sub-classes, irrespective of their clinical signs and symptoms."
Regina Fritsche-Danielson
Senior Vice President and Head of Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D
We have
179
projects in our pipeline
Corporate Press Release
Tezspire approved for self-administration in the EU in a new pre-filled pen
Corporate Press Release